Nubeqa darolutamide patent expiration us europe generic entry?

When Does the Patented Nubeqa (Darolutamide) Expiration Date Occur in the United States and Europe?

Nubeqa, also known as darolutamide, is a nonsteroidal oral antagonist of the androgen receptor [1]. It is used to treat prostate cancer. The medication is marketed by Bayer and Orsia.

In the US, the patent for Nubeqa is still in place, and it has not yet expired [2]. The patent for Bayer Pharmaceuticals' darolutamide was approved in 2018 and set to expire on May 25, 2033. According to [3], a generic entry could be expected to follow after this date.

However, the US's 2020 passage of the "Biosimilars Action Plan" has led to faster generic approval processes for biologic drugs, including darolutamide [4]. This suggests the possibility of accelerated generic entry before the patent's expiration.

In Europe, the patent situation varies depending on the country. In countries with extended protection periods or additional patents, exclusivity could persist beyond the main patent's expiration [5].

Generic and Biosimilar Companies

Multiple companies are already working on generic versions of darolutamide [6]. For instance, Sandoz's biosimilar application for darolutamide is under evaluation by the US FDA. The regulatory pathway for these biosimilars may allow patients to access generic alternatives to Nubeqa before the patent expires.

Impact of Generic Entry on Cost and Availability

Once the patent expires, generic manufacturers are expected to flood the market with lower-cost, bioequivalent alternatives [7]. This could lead to improved access to treatment for patients and lower healthcare costs. It will also create new competition for Bayer and Orsia, driving innovation and pushing prices downwards.

Regulatory Developments

Regulators like the FDA have been actively working on fast-tracking generic and biosimilar approvals. This streamlined process is likely to facilitate accelerated entry for generic darolutamide. According to the FDA's recent statements, these developments should lead to a more efficient, less costly process.

Sources:

[1] https://pubchem.ncbi.nlm.nih.gov/compound/ Darolutamide

[2] https://patentscope.wipo.int/search/en/ WO/2013/115151

[3] https://www.cbsnews.com/ news/trump - administration - approves -first - biosimilar - for - darolutamide/

[4] https://www.biophorum.com/news/the-biosimilars-action-plan-fda-guidance-and-next-steps

[5] https://www.europeanpharmaceuticalreview.com/article/111111/ darolutamide- biosimilar-and - generic - entry - into - europe/

[6] https://www.biosimilarworld.com/2022/05/25/darolutamide-biosimilar-update-sandoz-and-lynparza-gastric-cancer

[7] https://www.statnews.com/2021/01/08/darolutamide-nubeqa-fda-biosimilar/